Mersana Therapeutics Inc

NASDAQ:MRSN  
6.16
-0.48 (-7.16%)
Products

Mersana Therapeutics Announces FDA Fast Track Designation Granted To Xmt-1660 For The Treatment Of Triple-Negative Breast Cancer

Published: 09/12/2022 12:49 GMT
Mersana Therapeutics Inc (MRSN) - Mersana Therapeutics Announces FDA Fast Track Designation Granted to Xmt-1660 for the Treatment of Triple-negative Breast Cancer.